The present study confirms the tolerability of dapagliflozin
as add-on to metformin. Treatment was associated with a
10-fold lower incidence of hypoglycaemia compared with glipizide
add-on to metformin, with most episodes being minor in
severity. This corroborates findings from an earlier study [13],
in which the rate of dapagliflozin-associated hypoglycaemia
was significantly lower than that observed with glipizide (3.5
vs 40.8%).